Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 7/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 4/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3314974 | 0.91 | KIFC1 (0.37) | ADRB2ITGB1ITGA4ITGB7PPARG | |
| SCHEMBL3309182 | 0.81 | ACE (0.49) | ADRB2ADRB1ITGB1ITGA4ITGB7 | |
| SCHEMBL1206717 | 0.79 | ADRB2 (0.41) | ADRB2ADRB1AKR1C3AKR1C2PPARG | |
| SCHEMBL3309849 | 0.79 | GRB2 (0.44) | ADRB2ADRB1PPARGPPARA | |
| SCHEMBL1206720 | 0.79 | ADRB2 (0.41) | ADRB2ADRB1AKR1C3AKR1C2PPARG | |
| SCHEMBL3309854 | 0.79 | GRB2 (0.44) | ADRB2ADRB1PPARGPPARA | |
| Hydrochloric Acid SCHEMBL3311854 | 0.78 | GRB2 (0.43) | ADRB2ADRB1 | |
| SCHEMBL6779095 | 0.77 | CA2 (0.41) | AKR1C2 | |
| Hydrochloric Acid SCHEMBL6779382 | 0.76 | CA2 (0.41) | AKR1C2 | |
| SCHEMBL3520174 | 0.76 | CPA1 (0.44) | ADRB2ADRB1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | ADRB2 63/4885ADRB1 39/4885ITGB1 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.